Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bio-Rad Laboratories ( (BIO) ) just unveiled an update.
Bio-Rad Laboratories, Inc. announced on February 13, 2025, that it had entered into a binding offer to acquire all equity interests of Stilla Technologies, a French corporation. The acquisition was completed by an affiliate of Bio-Rad on June 30, 2025, marking a significant expansion of the company’s operations.
The most recent analyst rating on (BIO) stock is a Buy with a $390.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Neutral.
The overall stock score for Bio-Rad Laboratories reflects significant financial challenges, including declining revenues and net losses, which are the most impactful factors. The technical analysis provides mixed signals, with no clear trend, and valuation metrics are unattractive due to the negative P/E ratio. The earnings call offered some positive developments but was overshadowed by substantial challenges. The company’s ability to improve operational efficiencies and revenue growth will be critical for future performance.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Average Trading Volume: 394,184
Technical Sentiment Signal: Sell
Current Market Cap: $6.64B
For an in-depth examination of BIO stock, go to TipRanks’ Overview page.